Proton pump inhibitors and peptic ulcer management: Antioxidant mechanisms
Abstract
Peptic ulcer (P.U.) is the gastrointestinal tract's most frequent disorder affecting mainly the stomach and duodenum. Surgical intervention, ingested materials and microbial infections may trigger inflammation that further predispose to oxidative stress. Proton pump inhibitors (PPIs) are group of compounds established for suppressions of gastric acid secretions profoundly and permanently over a reasonably long period of time. Oxidative stress has been shown to be involved in the pathophysiology of various diseases and disorders, including P.U. Particularly when H. pylori infection accompanies it. In addition to the colonization of this microorganism, gastric mucosa may be subjected to extreme oxidative stress with large levels of inflammatory cell aggregation, which may eventually predispose to the disorder. PPIs exert several effects other than gastric acid suppression that can be used to treat Helicobacter pylori infections, disorders of the respiratory tract, viral infections, and other conditions related to dysfunction of endothelium by activating endogenous antioxidant protection and reducing the release of cytokine. Recent therapeutic protocols have recommended PPIs as gastro-protective compounds not only because of their acid suppression properties, but also because of their potent antioxidant and anti-inflammatory properties.
Keywords: Proton Pump Inhibitors, Peptic Ulcer, Oxidative Stress, H. pylori
Keywords:
Proton Pump Inhibitors, Peptic Ulcer, Oxidative Stress, H. pyloriDOI
https://doi.org/10.22270/jddt.v11i4-S.4955References
N. S, P. R. Introduction to PUD - A review. J Pharm Res 2017;11:878–86.
Kuna L, Jakab J, Smolic R, Raguz-Lucic N, Vcev A, et al. Peptic Ulcer Disease: A Brief Review of Conventional Therapy and Herbal Treatment Options. J Clin Med 2019; 8:179. https://doi.org/10.3390/jcm8020179.
Tarasconi A, Coccolini F, Biffl WL, Tomasoni M, Ansaloni L, et al. Perforated and bleeding peptic ulcer: WSES guidelines. World J Emerg Surg 2020; 15:3. https://doi.org/10.1186/s13017-019-0283-9.
VOMERO ND, COLPO E. Nutritional care in peptic ulcer. ABCD Arq Bras Cir Dig (São Paulo) 2014; 27:298–302. https://doi.org/10.1590/S0102-67202014000400017.
Kavitt RT, Lipowska AM, Anyane-Yeboa A, Gralnek IM. Diagnosis and treatment of peptic ulcer disease. Am J Med 2019; 132:447–56. https://doi.org/10.1016/j.amjmed.2018.12.009
Amandeep K, Robin S, Ramica S, Sunil K. Peptic Ulcer: a Review on Etiology and Pathogenesis. Int Res J Pharm 2012;3:34–8.
Kulshreshtha M, Srivastava G, Singh M. Pathophysiological status and nutritional therapy of peptic ulcer: An update. Environ Dis 2017; 2:76. https://doi.org/10.4103/ed.ed_11_17.
Malfertheiner P, Schulz C. Peptic Ulcer: Chapter Closed? Dig Dis 2020; 38:112–6. https://doi.org/10.1159/000505367.
Bhattacharyya A, Chattopadhyay R, Mitra S, Crowe SE. Oxidative Stress: An Essential Factor in the Pathogenesis of Gastrointestinal Mucosal Diseases. Physiol Rev 2014; 94:329–54. https://doi.org/10.1152/physrev.00040.2012.
Suzuki H, Nishizawa T, Tsugawa H, Mogami S, Hibi T. Roles of oxidative stress in stomach disorders. J Clin Biochem Nutr 2012; 50:35–9. https://doi.org/10.3164/jcbn.11-115SR.
Nita M, Grzybowski A. The Role of the Reactive Oxygen Species and Oxidative Stress in the Pathomechanism of the Age-Related Ocular Diseases and Other Pathologies of the Anterior and Posterior Eye Segments in Adults. Oxid Med Cell Longev 2016; 2016:1–23. https://doi.org/10.1155/2016/3164734.
Priya G, Parminder N, Jaspreet S. Oxidative Stress Induced Ulcer Protected By Natural Antioxidants: a Review. Int Res J Pharm 2012; 3:76–81.
Kwiecien S, Jasnos K, Magierowski M, Sliwowski Z, Pajdo R, et al. Lipid peroxidation, reactive oxygen species and antioxidative factors in the pathogenesis of gastric mucosal lesions and mechanism of protection against oxidative stress - induced gastric injury. J Physiol Pharmacol 2014; 65:613–22.
Sachs G, Shin JM, Howden CW. Review article: The clinical pharmacology of proton pump inhibitors. Aliment. Pharmacol. Ther., 2006. https://doi.org/10.1111/j.1365-2036.2006.02943.x.
Mullin JM, Gabello M, Murray LJ, Farrell CP, Bellows J, et al. Proton pump inhibitors: actions and reactions. Drug Discov Today 2009. https://doi.org/10.1016/j.drudis.2009.03.014.
Shin JM, Sachs G. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep 2008; 10:528–34. https://doi.org/10.1007/s11894-008-0098-4.
Shin JM, Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil 2013. https://doi.org/10.5056/jnm.2013.19.1.25.
Shoman A, Badwy A, Elhammady M, Eldesoki Y. Effect of Proton Pump Inhibitors, Vitamin E and their co- administration on heart function and Oxidative Changes in Isoprenaline Induced Myocardial Infarction in Adult Male Albino Rats. Benha Med J 2020; 0:0–0. https://doi.org/10.21608/bmfj.2020.77404.
Onda K, Tong S, Beard S, Binder N, Muto M, et al. Proton Pump Inhibitors Decrease Soluble fms-Like Tyrosine Kinase-1 and Soluble Endoglin Secretion, Decrease Hypertension, and Rescue Endothelial Dysfunction. Hypertension 2017; 69:457–68. https://doi.org/10.1161/HYPERTENSIONAHA.116.08408.
Yu L-Y, Sun L-N, Zhang X-H, Li Y-Q, Yu L, et al. A review of the novel application and potential adverse effects of proton pump inhibitors. Adv Ther 2017; 34:1070–86. https://doi.org/10.1007/s12325-017-0532-9.
Kedika RR, Souza RF, Spechler SJ. Potential Anti-inflammatory Effects of Proton Pump Inhibitors: A Review and Discussion of the Clinical Implications. Dig Dis Sci 2009; 54:2312–7. https://doi.org/10.1007/s10620-009-0951-9.
Biswas S, Benedict SH, Lynch SG, LeVine SM. Potential immunological consequences of pharmacological suppression of gastric acid production in patients with multiple sclerosis. BMC Med 2012; 10:57. https://doi.org/10.1186/1741-7015-10-57.
Chanchal SK, Mahajan UB, Siddharth S, Reddy N, Goyal SN, et al. In vivo and in vitro protective effects of omeprazole against neuropathic pain. Sci Rep 2016; 6:30007. https://doi.org/10.1038/srep30007.
Biswas K, Bandyopadhyay U, Chattopadhyay I, Varadaraj A, Ali E, et al. A Novel Antioxidant and Antiapoptotic Role of Omeprazole to Block Gastric Ulcer through Scavenging of Hydroxyl Radical. J Biol Chem 2003; 278:10993–1001. https://doi.org/10.1074/jbc.M210328200.
Eltahir HM, Nazmy MH. Esomeprazole ameliorates CCl4 induced liver fibrosis in rats via modulating oxidative stress, inflammatory, fibrogenic and apoptotic markers. Biomed Pharmacother 2018; 97:1356–65. https://doi.org/10.1016/j.biopha.2017.11.028.
Xie W, Huang X, Chen R, Chen R, Li T, et al. Esomeprazole alleviates the damage to stress ulcer in rats through not only its antisecretory effect but its antioxidant effect by inactivating the p38 MAPK and NF-κB signaling pathways. Drug Des Devel Ther 2019; 13:2969–84. https://doi.org/10.2147/DDDT.S193641.
Agnihotri N, Kaur H, Kaur N, Sarotra P. Role of oxidative stress in lansoprazole-mediated gastric and hepatic protection in Wistar rats. Indian J Gastroenterol 2007; 26:118–21.
Blandizzi C. Lansoprazole prevents experimental gastric injury induced by non-steroidal anti-inflammatory drugs through a reduction of mucosal oxidative damage. World J Gastroenterol 2005; 11:4052. https://doi.org/10.3748/wjg.v11.i26.4052.
Tabeefar H, Beigmohammadi MT, Javadi MR, Abdollahi M, Mahmoodpoor A, et al. Effects of Pantoprazole on Systemic and Gastric Pro- and Anti-inflammatory Cytokines in Critically Ill Patients. Iran J Pharm Res IJPR 2012; 11:1051–8. https://doi.org/10.22037/ijpr.2012.1196.
Swamy AHMV, Thippeswamy AHM, Sadiq A, Sajjan M, Koti B. Influence of proton pump inhibitors on dexamethasone-induced gastric mucosal damage in rats. Indian J Pharm Sci 2011; 73:193–8. https://doi.org/10.4103/0250-474X.91582.
Abed MN, Alassaf FA, Jasim MHM, Alfahad M, Qazzaz ME. Comparison of Antioxidant Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole. Pharmacology 2020:1–7. https://doi.org/10.1159/000506232.
Alfahad M, Qazzaz ME, Abed MN, Alassaf FA, Jasim MHM. Comparison of Anti-Oxidant Activity of Different Brands of Esomeprazole Available in Iraqi Pharmacies. Syst Rev Pharm 2020; 11:330–4. https://doi.org/10.31838/srp.2020.5.48.
Published
Abstract Display: 958 
PDF Downloads: 818 PDF Downloads: 58 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.